<DOC>
	<DOCNO>NCT01028651</DOCNO>
	<brief_summary>This multicenter , prospective , observational , open-label study . Patients meet inclusion/exclusion criterion receive treatment treprostinil recommend treat physician follow accord standard care . This observational study collect clinical data biologic specimens patient treat portopulmonary hypertension ( PoPH ) , goal achieve hemodynamic parameter appropriate orthotopic liver transplantation candidacy , include mean pulmonary arterial pressure ( mPAP ) less 35 mmHg pulmonary vascular resistance ( PVR ) less 3 Wood-units ( WU ) Week 24 patient severe PoPH .</brief_summary>
	<brief_title>A Study Assess Safety Efficacy Treprostinil Facilitate Liver Transplantation Patients With Portopulmonary Hypertension</brief_title>
	<detailed_description>Treprostinil approve continuous subcutaneous ( SC ) intravenous ( IV ) infusion FDA treatment WHO group I PAH New York Heart Association ( NYHA ) Functional Class II , III IV symptomatology . To date , treprostinil study set PoPH ; however , commonly prescribe set . This observational , open-label , multicenter study document safety efficacy profile agent PoPH facilitate orthotopic liver transplantation ( OLT ) .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Treprostinil</mesh_term>
	<criteria>Patients must : 1 . Had portal hypertension . 2 . Be otherwise suitable candidate OLT . 3 . Had severe pulmonary arterial hypertension ( PAH ) define rest mean pulmonary arterial pressure ( mPAP ) &gt; 35 mmHg pulmonary vascular resistance ( PVR ) ≥3 Wood Units ( WU ) right heart catheterization ( RHC ) perform part standard care evaluation within 90 day enrollment . 4 . Treprostinil therapy must recommend treat physician per standard care . 5 . Be NYHA Functional Class II , III , IV . 6 . Had pulmonary capillary wedge ( PCW ) pressure ≤18 mmHg transpulmonary gradient ( TPG ) ≥15 mmHg . Patients must : 1 . Had receive investigational therapy part clinical trial indication within 30 day prior enrollment . 2 . Had change dose treatment PAH ( bosentan [ Tracleer ] , ambrisentan [ Letairis ] , tadalafil [ Adcirca ] , sildenafil [ Revatio ] ) , within 30 day prior enrollment . That , subject may treat agent provide dose stable least 30 day prior enrollment . 3 . Had renal failure require hemodialysis .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>PAH</keyword>
	<keyword>Pulmonary Hypertension</keyword>
	<keyword>Remodulin</keyword>
	<keyword>Treprostinil</keyword>
	<keyword>Quality Life</keyword>
</DOC>